Harnessing Neuronal Autophagy: Bridging Mechanistic Breakthroughs to Therapeutic Interventions.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and therapeutic strategies without systematic review or new empirical human data
PubMed 42234962 · doi:10.14336/AD.2025.0804
What was done
This narrative review summarizes molecular mechanisms governing bulk and selective autophagy pathways in neurons and examines how mutations in autophagy-related and endolysosomal genes contribute to neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. It also surveys proposed therapeutic approaches aimed at restoring autophagic flux—including small molecules, gene therapies, and natural compounds—and notes ongoing clinical trials.
What was found
The abstract reports no quantitative data, effect sizes, or specific trial numbers. It presents a qualitative overview linking autophagy dysfunction, protein aggregation, and mitochondrial failure to neurodegeneration, asserting that therapeutic restoration of autophagic clearance remains a viable strategy across multiple disorders.
Why it matters
Provides a broad mechanistic overview of how autophagic pathways might be harnessed pharmacologically or genetically to clear toxic protein aggregates in neurodegenerative conditions.
Limits
As a narrative review, it introduces no primary empirical data, does not use systematic review methodology, and provides no quantitative metrics. The clinical viability, safety, and translatability of targeting autophagy in human patients cannot be evaluated from this record.
Cited by
- supports Most neurodegenerative diseases are caused by the accumulation of toxic protein aggregates resulting from either excessive unfolded protein production or deficiencies in autophagic and lysosomal machineries.